Similarly, Checkmate 012 [6], a phase 1 trial investigating first-line nivolumab monotherapy or in combination with standard therapies for NSCLC demonstrated no meaningful activity in EGFR-mutated tumors. Here, EGFR is linked to non-small cell lung carcinoma.